


Inside the Peri-implant Inflammatory Lesion: Immune Signalling, Bone Resorption, and Systemic Context

An evidence-based guide to lesion biology, cytokine networks, osteoclast activation and cautious causal interpretation



Conceptual scientific illustration. Cellular forms and signalling effects are illustrative.

Core message: peri-implantitis produces an intense local immune lesion in which cytokine networks connect microbial challenge with connective-tissue injury and osteoclast-mediated bone loss. Systemic consequences require separate evidence.

Educational material for dental students, postgraduate trainees and academic teachers

Inflammatory biology and evidence boundaries

Peri-implantitis is a biofilm-associated inflammatory disease in which microbial challenge and the host response interact within a structurally vulnerable peri-implant tissue compartment. Neutrophils, macrophages, T lymphocytes, B lymphocytes and plasma cells form a dense lesion, while cytokines, chemokines, proteolytic enzymes and reactive mediators contribute to connective-tissue injury.

Local inflammatory process

Inflammatory signalling links the soft-tissue lesion with bone remodelling. Increased osteoclast differentiation and activity shift the balance towards resorption of supporting bone. Interleukin-1 family mediators, tumour necrosis factor and the RANK-RANKL-osteoprotegerin axis participate in this network, but no single mediator represents the entire biological process or reliably defines the stage of disease.

Biomarkers and systemic context

Peri-implant crevicular fluid reflects the local environment next to the sampled implant surface. Its composition depends on lesion activity as well as collection and assay methods. Circulating inflammatory markers may be higher in some patients with peri-implantitis, although shared risk factors, reverse causation and study heterogeneity prevent a simple causal interpretation. Biomarker findings therefore complement clinical and radiographic assessment rather than replacing it.

Evidence boundary

The strongest evidence concerns local tissues and local fluid samples. Studies consistently identify inflammatory cells and elevated mediators at diseased sites. Observational studies also report higher circulating inflammatory markers in some patients with peri-implantitis, but those findings do not establish the direction or cause of the association.

Clinical boundary

Treatment endpoints remain local: reduce bleeding and suppuration, decrease pathological pocket depth, arrest bone loss and restore maintainability. Current evidence does not justify promising systemic benefit from peri-implant therapy.

Local mechanism and systemic effect are different claims. Evidence for one cannot be used automatically to prove the other.

The peri-implant inflammatory lesion

Peri-implant tissues differ from the periodontal attachment apparatus. Connective-tissue fibres do not insert into the implant surface, and the supracrestal zone has a different vascular arrangement. These anatomical features do not cause peri-implantitis, but they shape the route through which inflammation can extend towards the bone crest.

Cell population	Principal role in the lesion	Interpretive point
Neutrophils	Rapid antimicrobial response, phagocytosis and release of enzymes or reactive mediators.	Their prominence reflects an active microbial challenge.
Macrophages	Pathogen recognition, phagocytosis and amplification of cytokine signalling.	Phenotype and function vary across the lesion and disease stage.
T lymphocytes	Coordinate cellular immunity and influence inflammatory or regulatory pathways.	Their effects depend on local activation and cytokine context.
B lymphocytes and plasma cells	Support humoral responses and antibody production in chronic lesions.	Their proportions increase in established peri-implantitis compared with mucositis.

A cell-rich lesion

Histological studies describe peri-implantitis lesions rich in plasma cells and lymphocytes, with prominent neutrophils and macrophages. Lesions can extend apically and may occupy a larger area than corresponding periodontitis lesions. Lesion size indicates local inflammatory burden, but does not quantify systemic exposure.

Innate and adaptive immunity

Innate cells respond rapidly to microbial patterns and damaged tissue. Adaptive cells sustain more specific and chronic activity. The lesion represents a connected network rather than two separate systems: macrophage-derived mediators shape lymphocyte responses, while lymphocyte signals modify macrophage and osteoclast behaviour.

Anatomy modifies lesion behaviour. The implant-tissue interface provides less compartmentalisation than the attachment around a natural tooth.

Inflammatory mediators and their interpretation

Mediator	Evidence in peri-implant disease	Clinical limitation
IL-1 beta	Frequently elevated in mucositis and peri-implantitis compared with health.	Overlapping values may not separate mucositis from peri-implantitis.
TNF	Higher concentrations are reported at peri-implantitis sites and support a pro-inflammatory environment.	An elevated value does not identify lesion activity or prognosis on its own.
IL-1 alpha	Tissue studies identify a potential role in osteoclast-activating networks.	Biopsy data sample only part of the lesion and osseous interface.
IL-6	Associated with inflammatory signalling and sometimes elevated in local or circulating samples.	Assay methods and case definitions produce heterogeneous estimates.
IL-4 and IL-10	Differences between health and disease are less consistent.	Negative or overlapping results limit discriminatory use.
RANKL and OPG	Biologically link immune activity with osteoclast differentiation and control.	Human clinical findings do not consistently provide a reliable diagnostic threshold.

Networks rather than isolated molecules

Cytokines act through interacting pathways. The same mediator can influence endothelial activation, cell recruitment, matrix degradation or osteoclastogenesis depending on concentration, timing and the responding cell. A single value therefore captures only one point in a changing biological system.

Overlapping biomarker distributions

A marker can be statistically higher in diseased groups while still showing substantial overlap between individuals. Group differences support biological understanding, but diagnostic use requires validated cut-offs, reproducible sampling and performance that adds value beyond clinical examination.

A higher group mean is not a diagnostic threshold. Clinical utility requires sensitivity, specificity, reproducibility and a defined decision consequence.

Host-mediated connective-tissue and bone loss

Bacteria provide the initiating challenge, while the host inflammatory response produces much of the structural damage. Persistent signalling recruits and activates inflammatory cells, increases proteolytic activity and changes regulation of bone remodelling.

Biological step	Mechanism	Tissue consequence
Microbial recognition	Pattern-recognition receptors detect microbial products and tissue damage.	Innate cells release cytokines and chemokines.
Cell recruitment	Chemotactic signals direct neutrophils, monocytes and lymphocytes into the lesion.	The inflammatory infiltrate expands and consumes local resources.
Matrix injury	Proteases and reactive mediators degrade collagen and extracellular matrix.	The soft-tissue barrier loses structural integrity.
Osteoclast activation	RANKL-related signalling and pro-inflammatory cytokines favour osteoclast differentiation and activity.	Supporting bone enters a resorptive state.
Progressive defect	Continued inflammation maintains an environment that favours tissue breakdown.	Bone loss deepens and the surface becomes harder to decontaminate.

Osteoimmunology

Osteoclasts derive from monocyte-macrophage lineage precursors. Their differentiation depends on macrophage colony-stimulating factor and RANKL signalling, while osteoprotegerin can limit RANKL activity. Pro-inflammatory cytokines influence this axis directly and indirectly through stromal, immune and bone cells.

Why bone loss can accelerate

As the defect enlarges, more rough implant surface becomes exposed and sheltered from hygiene. The new anatomy supports persistent biofilm, which can sustain the inflammatory network. This feedback offers a biological explanation for non-linear disease progression without implying that every lesion follows the same trajectory.

Bone resorption is host mediated. Microbial exposure starts the challenge, but immune and skeletal cells execute tissue breakdown.

Peri-implant crevicular fluid and local biomarkers

Peri-implant crevicular fluid samples the narrow compartment adjacent to the implant sulcus. It can contain cytokines, chemokines, matrix-degrading enzymes and bone-related mediators released from the lesion or surrounding tissues.

Variable	Why it matters	Source of variation
Sampling site	A focal lesion can differ substantially between implant surfaces.	Pooling sites may dilute active local signals.
Fluid volume	Inflamed sites often produce more exudate.	Concentration and total amount can lead to different conclusions.
Collection technique	Strip placement, duration and contamination influence recovery.	Blood, saliva or plaque can alter measured values.
Assay platform	Detection limits and antibody specificity determine analytical performance.	Studies using different assays may not be directly comparable.
Clinical definition	The health, mucositis or peri-implantitis label determines group assignment.	Inconsistent case definitions increase heterogeneity.

Potential value

IL-1 beta, TNF, IL-6, MMP-8 and other mediators may add evidence that an inflammatory lesion is present. Research continues to investigate panels rather than single markers because multiple pathways contribute to disease. Repeated sampling may eventually help assess activity or treatment response.

Current limitation

No biomarker panel has replaced bleeding, probing and radiographic comparison in routine diagnosis. Local concentration does not equal circulating exposure, and a high value at one site does not establish a systemic effect. Biomarkers remain adjunctive tools whose meaning depends on sampling and clinical context.

PICF is a local compartment. Findings near the implant should not be interpreted automatically as evidence of systemic mediator spillover.

Systemic inflammation: association and causality

A 2023 systematic review reported higher circulating C-reactive protein, IL-6 and white blood cell counts in patients with peri-implantitis than in controls. The CRP analysis showed very high heterogeneity. These findings support an association with systemic inflammatory burden, but they do not establish that peri-implantitis caused the circulating changes.

Challenge	How it can distort interpretation	Evidence needed
Confounding	Smoking, diabetes, periodontitis history, obesity or maintenance behaviour can influence both oral and systemic inflammation.	Careful adjustment, matching and sensitivity analyses.
Reverse causation	Systemic inflammatory or metabolic dysregulation may increase susceptibility to peri-implant disease.	Longitudinal data that establish the sequence of events.
Disease severity	Severe oral and systemic conditions may cluster in medically complex patients.	Dose-response analysis with comparable case definitions.
Measurement timing	A single blood sample and one oral examination cannot show directionality.	Repeated measures before and after incident disease or treatment.
Treatment effect	Local improvement does not prove systemic benefit unless circulating outcomes change beyond control effects.	Controlled interventional studies with prespecified systemic endpoints.

Biological plausibility

An inflamed vascular tissue interface can exchange cells, microbial products and mediators with the circulation. This makes systemic interaction biologically plausible. Plausibility is one part of causal reasoning, but it cannot establish the magnitude, direction or clinical relevance of an effect.

What treatment studies must show

A causal claim would become stronger if peri-implant therapy produced a reproducible change in systemic outcomes compared with an appropriate control, after adjustment for shared determinants and concurrent medical care. Current clinical goals should remain focused on local disease control.

Association is clinically relevant but causally incomplete. Communicate the finding without promising systemic improvement.

Evidence-based clinical communication

Evidence level	What can be stated	What should be avoided
Established local mechanism	Biofilm-associated inflammation creates a cell-rich lesion and host-mediated supporting bone loss.	Reducing the lesion to a single cytokine or immune cell.
Supported local biomarker association	Selected PICF mediators are higher in disease groups and reflect inflammatory activity.	Presenting a single biomarker as a validated stage or prognosis test.
Supported systemic association	Some studies report higher circulating inflammatory markers in peri-implantitis.	Claiming that peri-implantitis caused chronic systemic disease.
Emerging causal hypothesis	Mediator exchange and bidirectional effects are biologically plausible and under investigation.	Promising systemic benefit from local treatment.

Clinical implications

- Record chronic diseases, medication use and current medical control because they influence procedural safety and healing.
- Coordinate care when diabetes, cardiovascular risk, immunosuppression or antiresorptive medication changes treatment planning.
- Use clinical inflammation and radiographic progression as primary treatment indications.
- Present biomarkers as supplementary evidence when they are used.
- Avoid implying that successful peri-implantitis therapy will treat a systemic disease.

Treatment endpoints

Evaluate reduction in bleeding and suppuration, pocket-depth improvement where relevant, arrest of further radiographic bone loss and restoration of access for self-care and supportive therapy. These outcomes have direct clinical meaning and can be monitored reproducibly.

Clinical and biological synthesis

- Peri-implantitis contains a dense lesion in which innate and adaptive immune responses interact.
- IL-1 beta, TNF and related networks support inflammation and osteoclast activation, but no single marker defines disease stage.
- PICF reflects a local sampling compartment and is sensitive to collection and assay methods.
- Higher systemic inflammatory markers have been reported in peri-implantitis, but causality remains unproven.
- Patient communication should distinguish established local mechanisms from emerging systemic hypotheses.

Selected references

1. Berglundh T, Armitage G, Araujo MG, et al. Peri-implant diseases and conditions: consensus report of workgroup 4 of the 2017 World Workshop. *Journal of Clinical Periodontology*. 2018;45(Suppl 20):S286-S291. doi:10.1111/jcpe.12957.
2. Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. *Journal of Clinical Periodontology*. 2018;45(Suppl 20):S246-S266. doi:10.1111/jcpe.12954.
3. Herrera D, Berglundh T, Schwarz F, et al. Prevention and treatment of peri-implant diseases: the EFP S3 level clinical practice guideline. *Journal of Clinical Periodontology*. 2023;50(Suppl 26):4-76. doi:10.1111/jcpe.13823.
4. Yan Y, Orlandi M, Suvan J, et al. Association between peri-implantitis and systemic inflammation: a systematic review and meta-analysis. 2023. PubMed PMID:37691939.
5. Lumbikananda S, et al. Oral fluid biomarkers for peri-implantitis: a scoping review. 2024. PubMed PMID:38065782.
6. La Monaca G, et al. Biomarkers in peri-implant crevicular fluid of healthy implants and untreated peri-implant mucositis and peri-implantitis: a systematic review and meta-analysis. 2025. PubMed PMID:40101934.
7. Galarraga-Vinueza ME, et al. Prevalence, incidence, systemic, behavioral, and patient-related risk and protective factors for peri-implant diseases: an AO/AAP systematic review and meta-analysis. *Journal of Periodontology*. 2025. doi:10.1002/JPER.24-0154.
8. Wang HL, et al. AO/AAP consensus on prevention and management of peri-implant diseases and conditions: summary report. *Journal of Periodontology*. 2025. doi:10.1002/JPER.25-0270.

Educational use and limitations

This material is intended for education and does not replace individual clinical assessment, laboratory interpretation or medical consultation. Biomarker findings should be interpreted within the sampling method, assay characteristics, case definition and complete patient context.

This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.